Chanticleer — Sonnet BioTherapeutics Holdings — Investor Presentation (May 2024)
31 slides from Chanticleer's investor presentation, May 14, 2024
Slide 1: Powering a New Wave of Immune Therapeutics
§ SONNET BioTherapeutics POWERING A NEW WAVE OF IMMUNE THERAPEUTICS Corporate Presentation
Slide 2: Forward Looking Statements
FORWARD LOOKING STATEMENTS This presentation contains forward-looking statements about Sonnet BioTherapeutics based on management's current expectations which are subject to known and unknown uncertainties and risks. Words such as “anticipated,” “initiate,” “expect,” “intend,” “plan,” “believe,” “se
Slide 3: Powering a New Wave of Immune Therapeutics
Powering a New Wave of Immune Therapeutics CORPORATE FOCUS Prioritize development of assets with partnering interest Cost-cutting initiative to reduce operating expenses by approximately 30% Existing material supply agreement with Roche and J&d pipeline evaluation offer licensing expansion opportuni
Slide 4: Pipeline Overview
Pipeline Overview ROGRAM INDICATIONS DISCOVERY | PRECLINICAL | PHASE! | PHASE! | PHASEII | PARTNER Chemotherapy induced Peripheral Neuropathy (CIPN) ‘SON-080 (Low-dose IL-6) Diabetic Peripheral Neuropathy (OPN) iS Platinum-Resistant Ovarian : BE sonrziojiznas.tis sc unas > a x Qe Sonnet BioTherapeut
Slide 5: Sonnet Pipeline Targets
Sonnet Pipeline Targets Multiple Points of Intervention Tumor Antigen Mature Dendritic e Cell (antigen e presenting) IL-18 Naive ry T-cell ———————— Antigen asaieants Lymph | Tumor Effector cells: 4. Activate other immune cells Antigen Pes a ) 2. Kill “target cells” _@ : ; Activated T-cell Memory cel
Slide 6: FHAB Platform Technology
@ SONNET F,AB PLATFORM TECHNOLOGY
Slide 7: Sonnet's Technology Advantage
Sonnet’s Technology Advantage One owe payloads ame ataged wth, “heb treee FAB + en ‘SON-1010 binds to Avomin ‘Albumin ‘onde. M 95 tumor cet e tite Neutrophil eeelm tumor veseels ‘ME stiow pH Teall Dendritic cell Albumin binds Fein or the GP60 receptor on tumor vessel walls, ‘then is transported into
Slide 8: FHAB: Superior Uptake and Retention in Tumor Tissue
F,,AB: Superior Uptake and Retention in Tumor Tissue An in vivo demonstration of SPARC-mediated binding with optimized retention using albumin F,AB alone Anti-TGFB, no FAB Anti-TGFB-F,AB Results show F,,AB enhanced EPR = Efficacy Western blot of Mouse 4T1 (TGFB positive tumor@150mm?) extracts from m
Slide 9: Biodistribution Profile Using Radiolabeled mIL12-FHAB and mIL12
Biodistribution Profile Using Radiolabeled mIL12-FHAB and miL12 mlL12-FHAB Accumulates in Tumor and Draining Lymph Nodes Tumor Biodistribution 6HR 24HR a8 HR 96 HR Time 89zr-mniL12 m89Zr-miL12-FHAB Comparative time course accumulation in B16F10 melanoma tumors of ®°Zr-mIL12 versus ®°Zr-mIL12-FHAB at
Slide 10: FHAB: Enhanced Pharmacokinetic Characteristics
FAB: Enhanced Pharmacokinetic Characteristics Comparing the pharmacokinetic characteristics of naked IL-12 and IL-15 versus the same interleukins linked to Sonnet's F,AB Method: 8 mice C57B/ TP, age 9.5 weeks, dose IV, sacrificed @ 5, 15, 30 mins, 1, 2, 4, 8, 24 & 48 hrs. Serum tested by ELISA. —@-
Slide 11: FHAB: Defining A Better Platform Technology
FAB: Defining A Better Platform Technology p98 7) hes S PEG Fe/lgG & — DNA/ Viral & «) 1PEGIL2(actve) fy Gene Thera ad BS OQ eTecey Sonnet Fy,AB Constructs Albumin Binding ATTRIBUTES ‘QUALIFIER ATTRIGUTES QUALIFIER ATTRIBUTES QUALIFIER ATTRIBUTES QUALIFIER Mono or Bi- Mono or Bi Mode fasts Mode Mono
Slide 12: FHAB: Preclinical Proof-of-Concept
9 BioTherapeutics F,AB: PRECLINICAL PROOF- OF-CONCEPT
Slide 13: SON-1010: Reduces Tumor Growth in Mice
SON-1010: Reduces Tumor Growth in Mice IL12-F,,AB (1.3ug) vs IL-12 (30g) in B16F10 Melanoma ~~ Placebo 2857 IL-12 (1ug) and 1L12- A IL12-FHAB (1.34g) = Molar 0.949 of L-12 F,,AB (1.3yg) are molar te IL-12 (30ug) _ equivalent and have similar bioactivity, in vitro, however, in vivo, FyAB is 1500 1:30
Slide 14: SON-1210: Optimized Bispecific Activity
SON-1210: Optimized Bispecific Activity Lymphoblast proliferation assay (IL-12) IFN-y release assay (IL-12) 25000 ann 18000 0000 wo 0 ao! wot 1112 (R&D ref) e WH 1112 (Rad ref > 1112-F,AB-ILI5 (i 1L12-F,,AB-IL15 GB 112-F,AB [Agente pw Dose (pM) CTLL-2 proliferation assay (IL-15) 28 20 os moe 1L12-F,
Slide 15: Flow Cytometry Analysis
Flow Cytometry Analysis . 1L12-FHAB (11g) 1L12-FyAB-IL15 (5y1g) | 1L18-FHAB-4IL12 (5g) Comparison of Efficacy — ~ Tumor & Spleen Inhibition 37% Inhibition 78% Inhibition 65% Immune Cell Type Day 5, TV ~400mm* Tumor | Spleen | Tumor | Spleen | Tumor | Spleen Cell Population T cells 08 1.0 05 0.9 12 0
Slide 16: SON-1210: Positioned For Clinical Development
SON-1210: Positioned For Clinical Development B16F10 mouse model 2400 % Inhibition 2100 “© Tumor Bearing Placebo 89% -& Ayg L124 1900 1g ILA2-FYABILAS 78% -e Sug IL12-FABILIS 1500: 41% -® Sug IL15 and IL12 Ref 91% -® 5 ug IL12-ABD-L15 (x3) H Therapeétitic Payload A Tumor Volume (mm?) £3228 SON-1210
Slide 17: SON-1410: A Novel Bispecific
SON-1410: A Novel Bispecific IL18-F,,AB-IL12 showed statistically significant tumor size reduction versus placebo in a mouse melanoma study, as well as a dose response. eee Day0,SingleDose | Day8TumorVolume | Day 8 Percentage Tumor @ 100 mm? (mm? SEM), N=8 Tumor Shrinkage Placebo 1747 + 301 IL18-F,,
Slide 18: SON-1010: Clinical Program
9 BioTherapeutics SON-1010: CLINICAL PROGRAM
Slide 19: Clinical Program: SB101/SB102 Studies
Clinical Program: SB101/SB102 Stu $B102: SAD for PK/PD/FACS in Healthy n=31 i= Level Dose Level 2} | 100 nate vy Volunteers Dose Level Ell 180raka 200 nag (200 nik iL-42) 50 ngkg ead er: [a] Hench ctvks i= Level ] 50 nag avs ‘36 per cohort ome | 1502500099 ques SB101: Safety compared with rhIL-12, a
Slide 20: SB101: Safety Data
SB101: Safety Data 50 ng/kg 150 ngikg 150 300ngikg | 150>300ngikg | 150 > 540 ng/kg Tachycardia (Grade 1) 1 (33.3) Nausea (Grade 1) 1(83) Chills (Grade 1) 1(33.3) 133.3) Fatigue (Grade 1) 1(33.3) 1333) Injection site pain (Grade 1) 1(33.3) 3100.0) Pain (Grade 1) 1(333) Pyrexia (Grade 1) 1(33.3) 1(83
Slide 21: SB101 Cytokine Assay Results
SB101 Cytokine Assay Results Primary PD parameters included IFNy, IL-1, IL-2, IL-4, IL-6, IL-8, IL-10, and TNFa, assayed using the MSD platform Increases in IFNy (showing an IL-12 effect and potential for tumor control) were dose-related, controlled, and prolonged. SON-1010 induced IFNy with both th
Slide 22: SON-1010 Interim PK Analysis after Cohort
SON-1010 Interim PK Analysis after Cohort 3 » Typical dose-related increases were seen with SON-1010, with single compartment kinetics in cancer and the potential for two compartments in healthy volunteers % The preliminary geometric mean elimination half-life (ty) was 113 hours in SB101, compared t
Slide 23: SB101: Influence on Tumor
SB101: Influence on Tum cohort mt 32 cohort m2 32 © Poa Eny gf © soateny . sue ease Cohortms: = & a wo a2 Posen _ conten Cohort mab #3 a3 cohonms $8 33 Dayssince study start a The swimmers plot shows the status for each patient and whether they had PD or SD at study entry. If patients are clinically
Slide 24: SB101 Clinical Program: High Level Summary
SB101 Clinical Program: High Level Summary » Preliminary PK modeling suggests t,, in humans is ~120 hours ay | ee Q Compares favorably with rhIL-12 ty, of 5-12 hours monet vin ane wepecoata + No Dose Limiting Toxicities to date in 15 patients . » Mostly mild with very few more significant adverse ev
Slide 25: SON-1010: Proposed Development Pathway
SON- 1010: proposed Deve lopment Pathway / and Effic Mouse Tumor Model: NHP = Tox, PK, Combo anti-PD1& Repeat dose mIL12-F,,AB —> Ss§s ——— $B101, $B102 $B221 Studies Study pisses (w pop Pk) MTD in Phase 1b/2a| Phase 2b 7 advanced combo in Dose IX solid tumor, PROC Finding ae SAD in NHV POC (E-R) IN,
Slide 26: Next Steps
Next Steps 9 BioTherapeufics SON-1010 in Combination with atezolizumab (Tecentriq®) » $B221 Study: Collaboration with Roche/Genentech: Phase 1b/2a adaptive design study to assess the safety, tolerability, PK/PD, and POC of SON-1010 alone or in combination with atezolizumab in patients with platinum-
Slide 27: SON-1010 Executive Summary
SON-1010 EXECUTIVE SUMMARY » Next Generation Oncology Platform (F,,AB) Q Confers both tumor targeting and enhanced pharmacokinetics (PK) Q Fully human protein sequence, and thus, no predicted immunogenicity » Firstimmune activator with tumor-targeting functions on a proprietary F,,AB platform ® Enco
Slide 28: SON-080 (Low-Dose IL-6): CIPN and DPN
§ SONNET SON-080 (LOW-DOSE IL-6) CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY AND DIABETIC PERIPHERAL NEUROPATHY
Slide 29: IL-6 Is Neurotrophic
IL-6 Is Neurotrophic _- Myelin sheet ‘Stimulates production of Myelin Binding Protein (MBP) Epidermal Innervation reinstates nerve fiber density Neuron Nerve function — Sensory function Protects Neurons Reinstates nerve Normalizes sensations from excitotoxic injury conduction velocity Sensory Nerve
Slide 30: IL-6: Safe and Well Tolerated at the Target Dose
IL-6: Safe and Well Tolerated at the Target Dose Phase I/II Clinical Data Thrombocytopenia n= 213; all types also including Grade lll/V cancer 10 independent Phase I/Il studies Diverse antineoplastic therapies 0.25-32 pg/kg/day, or 5-20 yg/ka/TIW SC Up to 10 weeks DE EFFECT PROFILE SAFETY WINDOW SSQ
Slide 31: Corporate Summary
rporate Summary Immune Oncology Immune stimulation using a proprietary Fully Human Albumin Binding (F},AB) platform to target the tumor microenvironment Safety Single dose of SON-1010 shown to be safe and well tolerated in healthy volunteers. Multiple doses of SON-1010 shown to be safe with early cl
Sonnet BioTherapeutics Holdings — Investor Presentation (May 2024) on 6ix